Olaparib medical insurance reimbursement conditions

Olaparib is an oral PARP inhibitor used to treat certain types of cancer, including ovarian, breast and prostate cancer. It is jointly developed by AstraZeneca (AstraZeneca) and Merck (Merck & Co.). The main indications for Lynparza include ovarian cancer, breast cancer associated with BRCA1 or BRCA2 gene mutations, and castration-resistant prostate cancer with BRCA mutations.

Olaparib is currently on the market in China and has been included in medical insurance. Patients can purchase it domestically. Specifications 150mg*56 tablets are priced at about four to five thousand yuan. For specific prices and medical insurance reimbursement, please consult the local hospital pharmacy. The cheaper ones abroad are mainly generic drugs, mainly from Bangladesh and Laos. The price of 150mg*120 tablets is about 2,000 yuan, which is much cheaper than domestic drugs, and the ingredients are basically the same as the domestic original drugs.

Domestic medical insurance reimbursement is limited only to:

1. Maintenance therapy for treatment-naive adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who carry germline or somatic BRCA mutations (gBRCAm or sBRCAm) after achieving complete or partial response to first-line platinum-containing chemotherapy;

2． Maintenance therapy for adult patients with homologous recombination repair deficiency (HRD)-positive advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after achieving complete or partial response with first-line platinum-containing chemotherapy combined with bevacizumab;

3． Maintenance therapy for adult patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after achieving complete or partial response to platinum-containing chemotherapy;

4． Treatment of adults with metastatic castration-resistant prostate cancer who carry a germline or somatic BRCA mutation (gBRCAm or sBRCAm) and who have failed prior therapy, including a novel endocrine agent.

Common side effects of olaparib include nausea, fatigue, anemia, and gastrointestinal upset. Some patients may also experience more serious side effects such as leukopenia and thrombocytopenia. When using olaparib, patients need to regularly monitor blood indicators and communicate closely with their doctors to adjust treatment plans and manage side effects in a timely manner. Overall, the use of olaparib has been shown to have important clinical value in the treatment of many cancer patients.